
Quick take: The Helus psilocin depression trial reports a win over placebo, according to the company’s own press release.
Helus Pharma announced topline Phase 3 results on November 16 for HLP003, a deuterated form of psilocin. The study enrolled 222 adults with moderate to severe depression. All of them stayed on a stable antidepressant. In total, 112 people got HLP003 and 110 got placebo.
Now, the numbers. At week six, depression scores fell 19.5 points with HLP003 and 11.9 with placebo. That is a 7.6 point gap. Also, the company says 56.3 percent responded, compared with 28.2 percent on placebo. Remission hit 50.9 percent versus 18.2 percent.
What the Helus psilocin depression trial can’t tell us yet
These are topline figures from a press release, not a peer-reviewed paper. In fact, the release gives no dose details. Three treatment-related serious adverse events occurred. The company says most side effects were mild to moderate and mostly limited to dosing day.
Meanwhile, the road ahead is long. HLP003 has FDA Breakthrough Therapy designation, but the release gives no approval timeline. A second pivotal study should report in the fourth quarter of 2027. However, the company says there is no assurance of that.
For context, the study was randomized, double-blind and run at multiple sites. As a result, the comparison is cleaner than a small open-label trial. Also, the company says the gap showed up as early as day two, at 5.0 points. By week twelve, the difference was 7.0 points.
We love a placebo-controlled win. We also love seeing the full data before we throw a party. Still, 222 people is a real trial, and a 7.6 point gap is not small talk.
Why it matters to stoners: If results hold up, psychedelic medicine moves one step closer to a doctor’s office near us.
Also, see our post on the UCSF psychedelic study.

